News & Updates
Showing Neurology articles
Showing
Efgartigimod shows promise in treatment-resistant myasthenia gravis
Use of efgartigimod, a first-in-class investigational antibody fragment targeting the neonatal Fc receptor (FCRN), demonstrates both efficacy and safety in patients with refractory, treatment-resistant generalized myasthenia gravis (MG), as shown in a study presented at EAN 2024.
Anti-CD20 show promise in multiple sclerosis after alemtuzumab
Treatment with anti-CD20 monoclonal antibodies appears to be a viable option for patients with relapsing-remitting multiple sclerosis (RRMS) who have uncontrolled disease following the use of alemtuzumab therapy, suggests a study presented at EAN 2024.
Advanced imaging can identify ischaemic stroke patients for intra-arterial thrombectomy >6 hours from symptom onset
According to a study conducted by the University of Hong Kong (HKU) and Queen Mary Hospital (QMH) since mid-2018, advanced imaging can identify patients with acute ischaemic stroke for intra-arterial thrombectomy even beyond 6 hours from symptom onset.
Rituximab shows promise in management of neuropsychiatric SLE
Treatment with rituximab (RTX) in patients with moderate-to-severe neuropsychiatric (NP) systemic lupus erythematosus (SLE) appears to result in some improvements and to contribute to the use of a much lower steroid dose at 6 months, suggests a study presented at EULAR 2024.
Reduced-dose DOACs tied to lower stroke incidence vs warfarin
Patients with atrial fibrillation receiving a reduced dose of direct acting oral anticoagulants (DOAC), particularly rivaroxaban and dabigatran, show a similar incidence of ischaemic stroke and systemic embolism to those receiving warfarin, a study has shown.
